Wednesday, December 6, 2023
Individuals with HIV who are heavily treatment-experienced with viremia and resistance -- whether they are older patients who sequenced through many nonsuppressive regimens, or adolescents/young adults who have survived perinatal HIV acquisition with limited antiretroviral agents available to them and despite adherence issues -- have limited treatment options, even in the current era with 7 classes of active drugs. These patients require highly individualized care from or in consultation with a specialist with experience evaluating and managing this niche population to select a regimen with at least 2 active drugs from at least 2 classes. In this collection of activities, leading experts in HIV medicine explore these challenges and offer practical guidance on how to evaluate patients in order to select for them a fully active antiretroviral regimen.
Professor of Medicine
Division of Infectious Diseases
Site Leader, HIV Prevention and Treatment Clinical Trials Unit at Chapel Hill
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
Washington, D.C.
Associate Professor of Medicine
Duke University School of Medicine
Durham, North Carolina
Professor of Medicine
Harvard Medical School
Clinical Director of the Division of Infectious Diseases
Brigham and Women's Hospital
Boston, Massachusetts
The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.
Medscape Education© Medscape, LLC
Dr David Wohl answers questions submitted by Medscape members.
Dr Rick Elion answers questions submitted by Medscape members, including questions on long-term management of HIV during the
COVID-19 pandemic.
Dr Paul Sax answers questions submitted by Medscape members.
Heavily treatment-experienced patients with HIV and virologic failure are rare in the current era. Do you know their treatment
options?
You may have never seen the consequences of being heavily HIV treatment experienced. Would you know it if you saw it?